抗白细胞介素-1药物用于心包炎:心内科医生入门指南
抗IL-1药物包括阿那白滞素、利纳西普和卡那奴单抗,用于治疗复发性特发性心包炎。对于激素依赖和秋水仙碱抵抗、CRP升高的复发性心包炎患者,阿那白滞素和利纳西普的疗效与安全性已在观察性研究和随机对照试验中得到证实,严重副作用罕见,停药率低于4%,最常见为注射部位反应。
要点
- 抗IL-1药物是复发性特发性心包炎的重要治疗选择。
- 阿那白滞素和利纳西普适用于激素依赖、秋水仙碱抵抗且CRP升高的患者。
- 严重副作用罕见,停药率低于4%,注射部位反应最常见。
核心结论
- 抗IL-1药物是近5年复发性心包炎药物治疗中最显著的进展。
研究设计与样本
- 综述,描述历史与病理生理背景,并全面回顾抗IL-1药物。
主要发现
- IL-1α和IL-1β过度产生是复发性特发性心包炎的治疗靶点。
- 阿那白滞素和利纳西普的疗效与安全性已在观察性研究和随机对照试验中证实。
- 严重副作用罕见,停药率低于4%,注射部位反应见于超过50%的患者。
关键数值与推荐
- 阿那白滞素:2 mg/kg/天至最大100 mg/天皮下注射,通常至少6个月后减量。
- 利纳西普:首日320 mg皮下注射,之后每周160 mg皮下注射。
- 适用人群:激素依赖和秋水仙碱抵抗的复发性心包炎,且有全身炎症证据(CRP升高)。
临床怎么用
- 对激素依赖和秋水仙碱抵抗的复发性心包炎患者,可考虑使用阿那白滞素或利纳西普。
- 使用前应确认CRP升高等全身炎症证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-interleukin (IL)-1 agents have been developed for the treatment of autoinflammatory and rheumatic conditions, where overproduction of IL-1 is an important pathophysiologic process. IL-1α and IL-1β are the most studied members of the IL-1 family of cytokines and have the strongest proinflammatory effects. A naturally occurring antagonist (IL-1Ra) mitigates their proinflammatory effects. Overproduction of both IL-1α (released by inflamed/damaged pericardial cells) and IL-1β (released by inflammatory cells) is now a well-recognized therapeutic target in patients with recurrent idiopathic pericarditis. Currently, there are three available anti-IL-1 agents: anakinra (recombinant human IL-1Ra), rilonacept (a soluble decoy receptor 'trap', binding both IL-1α and IL-1β), and canakinumab (human monoclonal anti-IL-1β antibody). For patients with corticosteroid-dependent and colchicine-resistant recurrent pericarditis with evidence of systemic inflammation, as evidenced by elevated C-reactive protein, the efficacy and safety of anakinra (2 mg/kg/day up to 100 mg/day subcutaneously usually for at least 6 months, then tapered) and rilonacept (320 mg subcutaneously for the first day followed by 160 mg subcutaneously weekly) have been clearly demonstrated in observational studies and randomized controlled clinical trials. Severe side effects are rare and discontinuation rates are very low (<4%). The most common reported side effect is injection site reactions (>50% of patients). In this article, we describe the historical and pathophysiological background and provide a comprehensive review of these agents, which appear to be the most significant advance in medical therapy of recurrent pericarditis in the last 5 years.
引用
- Imazio M, Lazaros G, Gattorno M, et al. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. Eur Heart J. 2022. PMID: 34528670. doi:10.1093/eurheartj/ehab452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。